nandrolone phenylpropionate

Cefuroxime, suppressing the intestinal flora, interferes with the synthesis . Therefore, while the appointment of drugs that reduce platelet aggregation nandrolone phenylpropionate, increases the risk of bleeding. For the same reason, while the appointment with anticoagulants has increased, the anticoagulant action.
When concomitant administration with diuretics, and potentially nephrotoxic antibiotics risk of nephrotoxicity increases. Simultaneous oral administration of “loop” diuretics slows tubular secretion and reduces the renal clearance, increases plasma concentration and increases T? cefuroxime. Probenecid reduces tubular secretion, reduces renal clearance.
Pharmaceutically compatible: with aqueous solutions containing 1% lidocaine hydrochloride, 0.9% sodium chloride, 5 and 10% dextrose, 0.18% sodium chloride and 4% dextrose ., 5% dextrose and 0.9% sodium chloride solution, Ringer’s solution, Hartmann’s solution, sodium lactate solution, heparinized (10 U / ml and 50 U / ml) in 0.9% sodium chloride solution
Pharmaceutically compatible: with solutions aminoglycosides (can not be mixed in the same syringe); with sodium hydrogen carbonate solution, 2.74%.

 

Special instructions:

Patients who had a history of allergic reaction to penicillin can be hypersensitivity to cephalosporin antibiotics. During treatment possible false-positive direct Coombs’ test and false positive reaction on urine glucose. Patients receiving cefuroxime, when determining the glucose concentration in the blood tests recommended for use with glucose oxidase or hexokinase. With prolonged use it is recommended to monitor renal function (especially when using high doses), and to carry out prevention of dysbiosis. Patients with impaired renal function, the dose should be reduced in view of the severity of renal insufficiency, and susceptibility.
After elimination of symptoms of the disease nandrolone phenylpropionate treatment should be continued for another 48-72 hours.

 

Product form:

Powder for solution for intramuscular and intravenous administration of 750 mg in a vial tsufuroksima transparent colorless glass type III, a sealed chlorobutyl nandrolone phenylpropionate rubber stopper and crimped aluminum cap, cap with snap-red. One bottle with instruction on use is placed in a cardboard box. From 50 to 100 vials, together with instructions for use placed in a cardboard box (for hospitals).

admin